drugset / Trial / NCT01974323

Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974323

Phase 3 Completed 2238 enrolled Almirall, S.A. Allergan · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.

Timeline

Start
2013-11
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapsone Small molecule 7.5 % Topical

Indications